Adenosine Analogs: Therapeutics for Hematologic Cancers
Adenosine Analogs: Therapeutics for Hematologic Cancers
批准号:
7126444
负责人:
STEVEN Terry ROSEN
金额:
$32.18万
依托单位国家:
美国
项目类别:
财政年份:
2005
资助国家:
美国
项目状态:
已结题
起止时间:
2005-09-26 至 2010-07-31
关键词:
DNA directed DNA polymeraseadenine analogadenosineantineoplasticsapoptosiscell linechronic myelogenous leukemiaclinical researchcysteine endopeptidasesdrug screening /evaluationenzyme activityflow cytometrygene mutationhigh performance liquid chromatographyhuman subjectmitochondriamultiple myelomaneoplasm /cancer pharmacologynuclear magnetic resonance spectroscopynucleic acid biosynthesisnucleoside analognucleoside triphosphateoxidative phosphorylationpharmacokineticspolymerase chain reactionribonucleotide reductase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Multiple myeloma and chronic lymphocytic leukemia are composed of non- or slowly- replicating quiescent cell populations. Therefore, therapeutic approaches that do not target replicating DNA, but rather focus on transcription, translation, cellular bioenergy production, and critical molecular pathways may prove to be more effective. We have previously developed a halogenated ATP analog, 8-chloro-adenosine (8-CI-Ado) that has a unique RNA-directed mechanism of action. The special properties of this agent, two successful RAID awards, and availability of the GMP material has resulted in a clinical trial targeting patients with hematologic malignancies. The success of 8-CI-Ado stimulated our investigation of related analogs. We identified 8-amino-adenosine (8-NH2-Ado) and 8-azido-adenosine (8-N3-Ado) in this screen as having similar RNA-directed actions as the 8-CI-Ado halogenated congener. In preliminary studies, we have shown that 8-NH2-Ado actions are more potent and rapid than the halogenated congener. Most impressively, 8- NH2-Ado causes a massive accumulation of 8-NH2-ATP with a concomitant decrease in the endogenous ATP pools. In addition, there is a striking decrease in RNA synthesis, which is followed by a concurrent decrease in DNA synthesis. In this grant proposal, we will focus on the unique properties of 8-NH2-Ado and 8-N3-Ado in order to move these drugs forward to the clinical setting. In Aim I of this proposal, we will characterize the metabolism of these drugs, dissect their effects on mitochondria I function and the subsequent depletion of cellular bioenergy, and explore how these alterations may act on nucleic acid synthesis. In Aim II, we will further dissect the inhibitory actions toward RNA by examining changes in transcription and poly-adenylation. Finally, in Aim III, we will pursue the novel observation of decreased phosphorylation of key signaling pathways and how that impacts on apoptosis. Understanding the mechanisms underlying the actions of 8-modified adenosine analogs will allow for further rational drug design and lead to an identification of compounds that may complement the activity of these drugs in a therapeutic setting. Relevance to public health: These studies propose to investigate the mechanism of action of novel therapeutics that may be effective in treating slowly proliferating cancers of the blood such as multiple myeloma and chronic lymphocytic leukemia; cancers which are currently incurable.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel targeted therapies for HPV-associated Non-AIDS-defining cancers (Biospecimens/Biocohort)
-
批准号:10620083
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2022
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Genomic and Microenvironment Analysis of HIV-Associated Diffuse Large B-cell Lymphoma (Immuno/Microenvironment)
-
批准号:10620074
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2022
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Caribbean Investigation of Cancer Stigma and its effect on Cervical Cancer Screening and HPV Vaccination
-
批准号:10406126
-
项目类别:
-
资助金额:$21.96万
-
财政年份:2021
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Creating an Efficient Clinical Trial Build System Via the Clinical Trials Rapid Activation Consortium (CTRAC)
-
批准号:10227589
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2020
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy
-
批准号:10525229
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2018
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy
-
批准号:10057371
-
项目类别:
-
资助金额:$69.18万
-
财政年份:2018
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Targeting p38 gamma signaling to advance Cutaneous T Cell Lymphoma Therapy
-
批准号:10296667
-
项目类别:
-
资助金额:$67.8万
-
财政年份:2018
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
-
批准号:9243226
-
项目类别:
-
资助金额:$46.35万
-
财政年份:2016
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
-
批准号:9107212
-
项目类别:
-
资助金额:$49.94万
-
财政年份:2016
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
-
批准号:9900748
-
项目类别:
-
资助金额:$43.05万
-
财政年份:2016
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
-
批准号:9458707
-
项目类别:
-
资助金额:$48.0万
-
财政年份:2016
-
负责人:STEVEN Terry ROSEN
-
依托单位:
CTRP
-
批准号:8761092
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2013
-
负责人:STEVEN Terry ROSEN
-
依托单位:
CTLA
-
批准号:8761096
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2013
-
负责人:STEVEN Terry ROSEN
-
依托单位:
keck biophysics
-
批准号:8486520
-
项目类别:
-
资助金额:$19.16万
-
财政年份:2012
-
负责人:STEVEN Terry ROSEN
-
依托单位:
genomics
-
批准号:8486522
-
项目类别:
-
资助金额:$18.52万
-
财政年份:2012
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Administration
-
批准号:8561278
-
项目类别:
-
资助金额:$44.48万
-
财政年份:2012
-
负责人:STEVEN Terry ROSEN
-
依托单位:
transgenic and targeted mutagenesis
-
批准号:8486524
-
项目类别:
-
资助金额:$18.55万
-
财政年份:2012
-
负责人:STEVEN Terry ROSEN
-
依托单位:
The Robert H. Lurie Comprehensive Cancer Center
-
批准号:7939419
-
项目类别:
-
资助金额:$5.0万
-
财政年份:2009
-
负责人:STEVEN Terry ROSEN
-
依托单位:
The Robert H. Lurie Comprehensive Cancer Center
-
批准号:7941465
-
项目类别:
-
资助金额:$148.53万
-
财政年份:2009
-
负责人:STEVEN Terry ROSEN
-
依托单位:
Chicago Cancer Navigation Project
-
批准号:7941368
-
项目类别:
-
资助金额:$30.19万
-
财政年份:2009
-
负责人:STEVEN Terry ROSEN
-
依托单位: